 |
||||||||||||||
|
 |
June 29th, 2007 Octapharma at ISTH Congress, Geneva, July 6-12th
Octapharma will participate at the ISTH congress with a 200-sqm booth (N° 1111), presenting our whole Haemophilia product portfolio, i.e. Wilate®, Octanate®, Octanine F®, Nanotiv® and Octaplex®. In total, we have 14 Posters to display in the official poster area. In addition, 10 of these will be shown at our booth through-out the congress. Please view poster information here. During the congress Octapharma will host two Satellite Symposiums. You can find information here below: The first Satellite Symposium with the title “The role of VWF in preventing and treating FVIII-inhibitors – when science meets clinical experience” will address the underlying science of the role of VWF in FVIII-inhibitor immunology, shed some light on practical applications of pre-ITI in vitro comparison of FVIII-concentrates and present information on the design of prospective clinical studies tackling the question of the role of the FVIII-concentrate type on ITI success and inhibitor development. Most recent retrospective clinical experiences using different classes of FVIII-concentrates for ITI-treatment will be compared and presented as well as new findings from prospective GCP-studies on the incidence of inhibitors in PUPs.
The Program at a glance: “The role of VWF in preventing and treating FVIII-inhibitors – when science meets clinical experience” July 11, 18.30 – 20.30 in Cervin Room, Palexpo  Chairman`s introduction, D Lillicrap, Kingston, Canada The immunological role of VWF in preventing inhibitors and inducing immune tolerance – FVIII-endocytosis and B-cell modulation, S Lacroix-Desmazes, Paris Using VWF/FVIII in PUPs – an update on recent data, A Klukowska, Warsaw ObsITI – investigating the role of VWF in ITI, W Kreuz, C Königs, C Escuriola-Ettinghausen, Frankfurt Can in vitro testing help to optimize ITI-treatment?, E Berntorp, Malmö The Octanate ITI-experience in poor-prognosis patients, N Zozulya, MoscowView the program in full length here: Octapharma Symposium July 11th Our second satellite symposium with title “Shattering perceptions, setting new standards in VWD” will present Wilate® a new generation double-virus inactivated VWF/FVIII-concentrate for the treatment of VWD-patients. Building on pre-clinical and large prospective clinical studies in VWD-patients. We will present the summarized recent results of the clinical experience with Wilate® in prophylaxis, on demand-treatment and major surgeries.
Program at a glance “Shattering perceptions, setting new standards in VWD” July 12, 2007, 08.00 – 10.00 in Cervin Room, Palexpo Chairman`s introduction: Why do the characteristics and PK profile of a VWF product matter? C Kessler, Washington Static vs. dynamic VWF-functions – what is more relevant? Comparing VWF-functions under physiological flow conditions, C Kannicht, Berlin Prophylactic and on-demand treatment using the newest generation VWF/FVIII-concentrate – Wilate, E Berntorp, Malmö Major surgery in severe VWD patients - recent experiences with Wilate, J WyndigaView the program in full length here: Octapharma Symposium July 12th To learn more about our products, their characterization and composition, you are invited to try your luck at the Bowling Challenge or the Walk around Quiz. In the exciting Bowling challenge you will be asked to compete against four other contestants in an electronical quiz. The player with the highest score may proceed to the electronic Bowling experience. The Walk around Quiz is based on the 10 scientific posters displayed at our booth. One of our experienced Octapharma staff will accompany you on a walk through our booth with a small questionnaire. Octapharma is sponsor of five Young Investigator Awards, which will be presented during the congress to medical trainees and young scientists. We look forward to seeing you at our booth (N° 1111)! ISTH 2007 congress website (Please note that clicking on this link will take you outside of the Octapharma web site) © Octapharma AG, 2007 |
